SCHEMBL2885887

SCHEMBL2885887

CCOC(=O)c1sc(-c2ccc(F)cc2)nc1C

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 5/20 0.78
CDC7 O00311 5/20 0.73
DBF4 Q9UBU7 5/20 0.73
KDM4E B2RXH2 6/20 0.63
ALDH1A1 P00352 4/20 0.63
LMNA P02545 3/20 0.63
KMT2A Q03164 4/20 0.61
MEN1 O00255 3/20 0.61
SMN1; SMN2 Q16637 3/20 0.61
NPC1 O15118 2/20 0.59
RAB9A P51151 2/20 0.59
HPGD P15428 1/20 0.59
NFKB1 P19838 1/20 0.59
NFKB2 Q00653 1/20 0.59
RELA Q04206 1/20 0.59
MAPT P10636 3/20 0.59
HSP90AA1 P07900 1/20 0.58
CRHBP P24387 1/20 0.58
CRHR2 Q13324 1/20 0.58
PKM P14618 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14394992 0.89 CDC7 (0.73) TRPM8CDC7DBF4KDM4EALDH1A1
SCHEMBL892889 0.89 CDC7 (0.77) TRPM8CDC7DBF4KDM4EALDH1A1
SCHEMBL289746 0.89 TRPM8 (0.62) TRPM8CDC7DBF4KDM4EALDH1A1
SCHEMBL15049096 0.88 TRPM8 (1.00) TRPM8CDC7DBF4KDM4EKMT2A
SCHEMBL290384 0.87 CDC7 (0.75) TRPM8CDC7DBF4KDM4EALDH1A1
SCHEMBL18321052 0.86 KDM4E (0.62) TRPM8CDC7DBF4KDM4EALDH1A1
SCHEMBL2085303 0.86 CDC7 (0.73) TRPM8CDC7DBF4KDM4EALDH1A1
SCHEMBL289229 0.86 CDC7 (0.73) TRPM8CDC7DBF4KDM4EALDH1A1
SCHEMBL4464882 0.86 CDC7 (0.73) TRPM8CDC7DBF4KDM4EALDH1A1
SCHEMBL2823339 0.86 CDC7 (0.73) TRPM8CDC7DBF4KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108059607-B Sulfonylacetic acid or sulfonyl acetic acid derivative, and pharmaceutical composition, preparation method and application thereof 中国科学院上海药物研究所 2020-11-17 CN disclosed
EP-3124489-B1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2020-07-15 EP disclosed
EP-3124489-A1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS Fibrogen, Inc. (US) 2017-02-01 EP disclosed
EP-2016078-B1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2016-06-15 EP disclosed
US-7696223-B2 [(2-bromo-4-hydroxy-1-phenyl-1H-pyrrolo[2,3-c]pyridine-5-carbonyl)-amino]-acetic acid; modulates the stability and/or activity of hypoxia inducible factor (HIF) FIBROGEN, INC. (US) 2010-04-13 US disclosed
EP-2016078-A2 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN, INC. (US) 2009-01-21 EP disclosed
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. 2008-01-03 US disclosed
WO-2007115315-A2 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN, INC. (US) 2007-10-11 WO disclosed
US-20060122432-A1 Aryl piperidine derivatives and use thereof to reduce elevated levels of ldl-cholesterol GLAXO GROUP LIMITED (GB) 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122432-A1 Aryl piperidine derivatives and use thereof to reduce elevated levels of ldl-cholesterol LDLR, NR1H2, NR1H3 TRPM8 1654/4885CDC7 4404/4885DBF4 3817/4885
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN2 TRPM8 3499/4885CDC7 2482/4885DBF4 2072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.